FcγRIIIa receptor polymorphism influences NK cell mediated ADCC activity against HIV

BMC Infect Dis. 2019 Dec 16;19(1):1053. doi: 10.1186/s12879-019-4674-z.

Abstract

Background: HIV-specific Antibody Dependent Cell Cytotoxicity (ADCC) has shown to be important in HIV control and resistance. The ADCC is mediated primarily by natural killer cell activated through the binding of FcγRIIIa receptor to the Fc portion of antibody bound to the antigen expressed on the infected cells. However, no data is available on the influence of the polymorphism in FcγRIIIa receptor on HIV-specific ADCC response.

Methods: The Sanger's method of sequencing was used to sequence the exon of FcγRIIIa receptor while the ADCC activity was determined using NK cell activation assay. The polymorphism in FcγRIIIa receptor was assessed in HIV-infected Indian individuals with or without HIV-specific ADCC antibodies and its influence on the magnitude of HIV-specific ADCC responses was analyzed.

Results: Two polymorphisms: V176F (rs396991) and Y158H (rs396716) were observed. The Y158H polymorphism is reported for the first time in Indian population. Both, V176F (V/V genotype) (p = 0.004) and Y158H (Y/H genotype) (p = 0.032) were found to be significantly associated with higher magnitude of HIV-specific ADCC response.

Conclusion: The study underscores the role of polymorphism in the FcγRIIIa receptor on HIV-specific ADCC response and suggests that the screening of the individuals for FcγRIIIa-V176F and Y158H polymorphisms could be useful for prediction of efficient treatment in monoclonal antibody-based therapies aimed at ADCC in HIV infection.

Keywords: ADCC; FcγRIIIa-V176F polymorphism; FcγRIIIa-Y158H polymorphism; HIV; NK cells.

MeSH terms

  • Adolescent
  • Adult
  • Antibodies, Monoclonal / therapeutic use
  • Antibody-Dependent Cell Cytotoxicity / genetics*
  • Female
  • Gene Frequency / genetics
  • Genotype
  • HIV Antibodies / therapeutic use
  • HIV Infections / genetics*
  • HIV Infections / immunology*
  • HIV Infections / therapy
  • HIV-1 / immunology*
  • Humans
  • Immunotherapy
  • India
  • Killer Cells, Natural / immunology*
  • Male
  • Middle Aged
  • Polymorphism, Single Nucleotide / genetics*
  • Prognosis
  • Receptors, IgG / genetics*
  • Treatment Outcome
  • Viral Envelope Proteins / pharmacology
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • FCGR3A protein, human
  • HIV Antibodies
  • Receptors, IgG
  • Viral Envelope Proteins